Invention Grant
- Patent Title: Guanidino compounds
- Patent Title (中): 胍基化合物
-
Application No.: US10426937Application Date: 2003-04-30
-
Publication No.: US06960582B2Publication Date: 2005-11-01
- Inventor: Rustum Boyce , David Duhl
- Applicant: Rustum Boyce , David Duhl
- Applicant Address: US CA Emeryville
- Assignee: Chiron Corporation
- Current Assignee: Chiron Corporation
- Current Assignee Address: US CA Emeryville
- Agent Bernard P. Friedrichsen; Steven W. Collier; Alisa A. Harbin
- Main IPC: C07D401/12
- IPC: C07D401/12 ; A61K31/496 ; A61K31/519 ; A61K31/53 ; A61P3/04 ; A61P3/10 ; A61P7/00 ; A61P43/00 ; C07D209/46 ; C07D209/48 ; C07D217/24 ; C07D235/08 ; C07D235/10 ; C07D403/12 ; C07D487/02 ; A61K31/5375 ; C07D413/12

Abstract:
Compounds having the general structure II are provided: A is selected from the group consisting of C or CH and X and Y are independently selected from the group consisting of CH2, N, C═O, C═S, (CR6R7)n, S═O, SO2, O, NR9, S, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n where n is 1, 2, or 3. W is selected from the group consisting of and Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Compounds of formula II are agonists of the melanocortin-4 receptor (“MC4-R”) and therefore may have useful properties for controlling diseases related to MC4-R action in humans, such as obesity and type II diabetes.
Public/Granted literature
- US20040024211A1 Novel guanidino compounds Public/Granted day:2004-02-05
Information query